BridgeBio Pharma Total Current Liabilities 2018-2024 | BBIO

BridgeBio Pharma total current liabilities from 2018 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
BridgeBio Pharma Annual Total Current Liabilities
(Millions of US $)
2023 $144
2022 $121
2021 $135
2020 $96
2019 $60
2018 $33
2017 $
BridgeBio Pharma Quarterly Total Current Liabilities
(Millions of US $)
2024-09-30 $139
2024-06-30 $134
2024-03-31 $141
2023-12-31 $144
2023-09-30 $106
2023-06-30 $110
2023-03-31 $97
2022-12-31 $121
2022-09-30 $119
2022-06-30 $141
2022-03-31 $103
2021-12-31 $135
2021-09-30 $96
2021-06-30 $132
2021-03-31 $95
2020-12-31 $96
2020-09-30 $76
2020-06-30 $93
2020-03-31 $65
2019-12-31 $60
2019-09-30 $40
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00